Clinical trial · no report yet · Phase 3
NCT06671379
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
- NCT06671379 ↗
- Active, not recruiting
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SHR-A2009 monotherapy; platinum-based dual-agent chemotherapy
- Arms
- SHR-A2009 monotherapy · Experimental
- platinum-based dual-agent chemotherapy · Active comparator
- Enrollment
- 498
- Primary outcomes
- Progression-free survival (PFS) assessed by BICR according to RECIST v1.1
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Start
- Nov 29, 2024
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06671379 · updated Mar 19, 2026